Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arista Networks Inc (ANET) vs Novartis AG (NVS) Price & Performance

Arista Networks IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Arista Networks Inc vs Novartis AG — how do they compare? Arista Networks Inc trades at $209.29 (market cap $249.53B), while Novartis AG trades at $154.71 (market cap $295.37B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays a 3.07% dividend while Arista Networks Inc pays none. Which is the better fit depends on your goals.

ANETNVS
Market Cap
$249.53B$295.37B
Sector
TechnologyHealth
52-Week High
$197.85$168.62
52-Week Low
$116.13$119.31
Enterprise Value
$236.19B$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Arista Networks Inc

Arista Networks (ANET) trades at $209.29, up 9.28% in 24 hours, near its 52-week high. The stock exhibits bullish technical signals with strong moving average support. Fundamentally, revenue grew to $9.01B in 2025 with a 38.37% net margin, though valuation multiples like a 62.61 P/E are elevated. Recent quarters show consistent EPS beats, with Q2 2026 EPS of $1.02 exceeding expectations by 15%.

Outlook remains positive driven by AI data center demand, but risks include high valuation sensitivity and insider selling. Analyst consensus is strongly bullish with a $252.25 price target, implying 20% upside. Execution on AI networking growth and hyperscaler spending are key catalysts, while competition and margin pressure pose challenges.

Novartis AG

Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.

The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Arista Networks Inc

Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.

Read more on ANET

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS